Phase Therapeutics develops a novel ultracold cryoablation technology for tumor destruction. This system uniquely delivers cryoablation translumenally via flexible endoscopy for lung and pancreatic applications. The platform offers precise, real-time visualization and aims to establish ablation as a primary, single-outpatient procedure modality.
Funding
Funding not disclosed
Founders
Product
Problem
Many pancreatic tumors are inoperable, leaving patients with limited treatment options. Existing ablation techniques often lack precision and can cause significant collateral damage to surrounding tissues. There is a need for a more effective and less invasive method to target and destroy these tumors.
Solution
Phase Therapeutics has developed a cryoablation platform that delivers ultracold cryogen directly to pancreatic cancer tissue via endoscopic ultrasound. This translumenal approach allows for precise targeting of tumors while minimizing damage to surrounding healthy tissue. The technology aims to provide a single outpatient procedure that effectively halts tumor progression. The ultracold cryoablation process is designed to generate tumor-specific antigens, potentially stimulating an immune response against the cancer. The platform can also be leveraged for cryobiopsy.
Target Audience
The primary target audience includes oncologists and interventional gastroenterologists treating patients with inoperable pancreatic cancer, as well as pulmonologists.
Features
- Translumenal delivery of cryoablation via endoscopic ultrasound for pancreatic tumors
- Mixed-phase cryogen technology for rapid and ultracold ablation
- Real-time ablation visualization for precise targeting
- Minimized collateral damage to surrounding tissues
- Potential to generate an immunogenic response
- Can be combined with chemotherapy, immunotherapy, and radiation
- Cryogenerator applicable to all percutaneous ablation (Breast, Liver, Kidney, Prostate)
- Cryoablation delivery through a bronchoscope for lung applications